Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Northwest Biotherapeutics (NWBO) over the last 10 years, with Q3 2025 value amounting to -$12.5 million.

  • Northwest Biotherapeutics' Non Operating Income fell 17354.03% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.9 million, marking a year-over-year decrease of 28965.68%. This contributed to the annual value of -$17.3 million for FY2024, which is 14354.82% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Non Operating Income stood at -$12.5 million, which was down 17354.03% from -$599000.0 recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Non Operating Income high stood at $144.0 million for Q4 2021, and its period low was -$17.2 million during Q3 2022.
  • In the last 5 years, Northwest Biotherapeutics' Non Operating Income had a median value of -$1.9 million in 2022 and averaged $8.1 million.
  • In the last 5 years, Northwest Biotherapeutics' Non Operating Income skyrocketed by 21991.7% in 2023 and then crashed by 93467.81% in 2024.
  • Over the past 5 years, Northwest Biotherapeutics' Non Operating Income (Quarter) stood at $144.0 million in 2021, then tumbled by 107.03% to -$10.1 million in 2022, then skyrocketed by 111.51% to $1.2 million in 2023, then tumbled by 934.68% to -$9.7 million in 2024, then fell by 28.64% to -$12.5 million in 2025.
  • Its Non Operating Income stands at -$12.5 million for Q3 2025, versus -$599000.0 for Q2 2025 and -$2.0 million for Q1 2025.